Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer

被引:115
作者
Weir, L
Speers, C
D'yachkova, Y
Olivotto, IA
机构
[1] British Columbia Canc Agcy, Breast Canc Outcomes Unit, Radiat Therapy Program, Vancouver, BC V5Z 4E6, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1200/JCO.2002.07.112
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The objective of the study was to evaluate the association between the number of lymph nodes removed at axillary dissection and recurrence and survival for patients with node-negative invasive breast cancer. Patients and Methods: Subjects were 2,278 women with pathologically node-negative invasive breast cancer, diagnosed from 1989 to 1993 in British Columbia, Canada. Women aged greater than or equal to 90 years, with pure in-situ, bilateral invasive breast cancer or T4, N1, N2, or M1 stage, or who had axillary radiation were excluded. Two groups were defined for analysis: node-negative with no systemic therapy (n = 1,468) and node-negative with systemic therapy (n = 810). Median follow-up was 7.5 years. Prognostic variables assessed were age at diagnosis, tumor size, tumor grade, invasion of lymphatics, veins, or nerves, estrogen receptor status, and number of nodes removed. Results: For patients not receiving systemic therapy, regional relapse was significantly increased with smaller numbers of nodes removed (P = .03). There was a trend toward shorter overall survival with fewer nodes removed (P = .06). Node-negative patients who received systemic therapy did not have a higher regional relapse rate or shorter overall survival when fewer nodes were recovered. Conclusion: Recovery of a small number of negative lymph nodes at axillary dissection likely understages patients and leads to undertreatment, resulting in an increased regional relapse rate and poorer survival. The use of systemic therapy may overcome this effect. The number of nodes removed, in conjunction with other prognostic factors, may be useful in selecting node-negative patients for systemic therapy. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:1793 / 1799
页数:7
相关论文
共 28 条
[1]   AXILLARY DISSECTION OF LEVEL-I AND LEVEL-II LYMPH-NODES IS IMPORTANT IN BREAST-CANCER CLASSIFICATION [J].
AXELSSON, CK ;
MOURIDSEN, HT ;
ZEDELER, K .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (8-9) :1415-1418
[2]   Axillary dissection in breast-conserving surgery for stage I and II breast cancer: A National Cancer Data Base Study of Patterns of Omission and Implications for Survival - Reply [J].
Bland, KI ;
Scott-Conner, CEH ;
Menck, H ;
Winchester, DP .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1999, 188 (06) :596-596
[3]   Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? - An algorithm for assessment of impact of axillary dissection [J].
Dees, EC ;
Shulman, LN ;
Souba, WW ;
Smith, BL .
ANNALS OF SURGERY, 1997, 226 (03) :279-286
[4]   The declining use of axillary dissection in patients with early stage breast cancer [J].
Du, XL ;
Freeman, JL ;
Goodwin, JS .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 53 (02) :137-144
[5]   PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP [J].
ELSTON, CW ;
ELLIS, IO .
HISTOPATHOLOGY, 1991, 19 (05) :403-410
[6]  
Fein DA, 1997, J SURG ONCOL, V65, P34, DOI 10.1002/(SICI)1096-9098(199705)65:1<34::AID-JSO7>3.0.CO
[7]  
2-P
[8]   THE EDINBURGH RANDOMIZED TRIAL OF AXILLARY SAMPLING OR CLEARANCE AFTER MASTECTOMY [J].
FORREST, APM ;
EVERINGTON, D ;
MCDONALD, CC ;
STEELE, RJC ;
CHETTY, U ;
STEWART, HJ .
BRITISH JOURNAL OF SURGERY, 1995, 82 (11) :1504-1508
[9]   Physical and psychological morbidity after axillary lymph node dissection for breast cancer [J].
Hack, TF ;
Cohen, L ;
Katz, J ;
Robson, LS ;
Goss, P .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :143-149
[10]  
Hermanek P, 1999, CANCER-AM CANCER SOC, V86, P2668, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2668::AID-CNCR11>3.3.CO